Joel Greenblatt Blueprint Medicines Corp Transaction History

Gotham Asset Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$45.23 - $70.15 $257,539 - $399,434	5,694 New	5,694 $288,000
Q3 2021 Nov 15, 2021	SELL	$80.98 - $109.47 $1.24 Million - $1.68 Million	-15,324 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$82.78 - $101.0 $645,187 - $787,194	7,794 Added 103.51%	15,324 $1.35 Million
Q1 2021 May 17, 2021	BUY	$90.71 - $108.28 $337,350 - $402,693	3,719 Added 97.59%	7,530 $732,000
Q4 2020 Feb 16, 2021	BUY	$92.08 - $124.48 $350,916 - $474,393	3,811 New	3,811 $427,000
Q3 2019 Nov 14, 2019	SELL	$72.9 - $101.41 $191,799 - $266,809	-2,631 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$73.54 - $97.8 $193,483 - $257,311	2,631 New	2,631 $248,000

350

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $6.57B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.